- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Concord Drugs Limited's Annual Secretarial Compliance Report for FY26 highlights several past compliance issues. These include a 27-day delay in submitting a regulatory report and missing mandatory disclosures on its website. Crucially, the company faced a fine of ₹0.02 Cr for not appointing a Company Secretary for two prior quarters (Q3FY24 and Q4FY24), which has since been paid. Management is actively addressing these challenges by updating its website and streamlining processes to ensure better adherence going forward.